NanoCelle® Fexodenadine

Product description

NanoCelle® Fexofenadine (as hydrochloride) is an oral-active non-sedating histamine H1-receptor antagonist.

IP RIGHTS:Patent Title: Transmucosal and transdermal delivery systems// NanoCelleJurisdiction: AustraliaApplication number: 2016226280Filing Date: 2nd March 16 Status: Accepted

Patent Title: Transmucosal and transdermal delivery systems// NanoCelleJurisdiction: CanadaApplication number: 2978179Filing Date: 2nd March 16 Status: Filed

Patent Title: Transmucosal and transdermal delivery systems// NanoCelleJurisdiction: EuropeApplication number: 16759418.3Filing Date: 2nd March 16 Status: Under examination

Patent Title: Transmucosal and transdermal delivery systems// NanoCelleJurisdiction: New ZealandApplication number: 735138Filing Date:  2nd March 2016 Status: Examination Requested

Patent Title: Transmucosal and transdermal delivery systems// NanoCelleJurisdiction: SingaporeApplication number: 11201707068XFiling Date: 2nd March 2016 Status: Under examination

Patent Title: Transmucosal and transdermal delivery systems// NanoCelleJurisdiction: United StatesApplication number: 15/555038 Filing Date: 2nd March 2016Status: Under examination

Patent Title: Transmucosal and transdermal delivery systems// NanoCelleJurisdiction: Hong KongApplication number: 18103321.4Filing Date: 2nd March 2016Status: Filed
Read more

Specifications

Categories Pharmaceutical Machinery & TechnologyBioavailability enhancement; Finished Dosage Forms
Sales markets Western Europe; Eastern Europe; Middle East Region (e.g. UAE); Oceania; North America (USA, Canada); Central/South America
Supplied from Australia

More products from Medlab Clinical LTD

View all our products (10)

Products from other suppliers